PharmaPart Report issue

For profit Phase 2 Phase 3
Founded: Thalwil Switzerland (1992)
Status: Acquired by Pierrel Research (2005)

Organization Overview

First Clinical Trial
2005
NCT00942591
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 3 Trials (1)

C1 Esterase Inhibitor (Human) (Cinryze) (1 trial)

Drugs in Phase 2 Trials (2)

atorvastatin (lipitor) (2 trials)

interferon beta-1b (betaseron) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Angioedema (Phase 3)

Angioedemas, Hereditary (Phase 3)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 3